These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25227171)

  • 1. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
    Kotulska K; Borkowska J; Mandera M; Roszkowski M; Jurkiewicz E; Grajkowska W; Bilska M; Jóźwiak S
    Childs Nerv Syst; 2014 Dec; 30(12):2037-42. PubMed ID: 25227171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
    Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
    Ichikawa T; Niida Y
    No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
    Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
    Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
    Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
    Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report.
    Beaumont TL; Godzik J; Dahiya S; Smyth MD
    J Neurosurg Pediatr; 2015 Aug; 16(2):134-7. PubMed ID: 25978531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report.
    Konakondla S; Jayarao M; Skrade J; Giannini C; Workman MJ; Morgan CJ
    Clin Neurol Neurosurg; 2016 Nov; 150():177-180. PubMed ID: 27690251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Curran MP
    Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSC2 somatic mosaic mutation, including extra-tumor tissue, may be the developmental cause of solitary subependymal giant cell astrocytoma.
    Sasaki T; Uda T; Kuki I; Kunihiro N; Okazaki S; Niida Y; Goto T
    Childs Nerv Syst; 2022 Jan; 38(1):77-83. PubMed ID: 34741623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
    Cappellano AM; Senerchia AA; Adolfo F; Paiva PM; Pinho R; Covic A; Cavalheiro S; Saba N
    Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subependymal giant-cell astrocytomas in the absence of tuberous sclerosis.
    Reynolds RA; Aum DJ; Gonzalez-Gomez I; Wong M; Roberts K; Dahiya S; Rodriguez LF; Roland JL; Smyth MD
    J Neurosurg Pediatr; 2023 Sep; 32(3):351-357. PubMed ID: 37327147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.